Oryzon Genomics is a clinical stage biopharmaceutical company that discovers, develops, and plans to commercialize novel epigenetic therapies to treat oncology and CNS diseases.
Our therapeutic strategy is to treat the underlying causes of these diseases by targeting lysine specific demethylase 1 (LSD1, also known as KDM1A). LSD1 is a histone modifying enzyme that is involved in the regulation of the expression of many genes important in the onset and progression of human diseases such as cancer and CNS disorders.
As reflected in the chart below, Oryzon has two drugs in Phase II clinical development: iadademstat (also known as ORY-1001), a selective LSD1 inhibitor for oncology, and vafidemstat (also known as ORY-2001), a CNS optimized LSD1 inhibitor for CNS and psychiatric disorders. Our pipeline also includes another LSD1 inhibitor, ORY-3001, in preclinical development for the treatment of non-oncological diseases, and additional programs at earlier stages of development.